Literature DB >> 20370673

Role of adipocytokines in hepatic fibrosis.

C Bertolani1, F Marra.   

Abstract

Hepatic fibrosis is a dynamic process whereby the liver responds to conditions of persistent damage. This leads to deposition of fibrillar extracellular matrix, altered hepatocyte regeneration, deranged microvascular architecture and cirrhosis. Accumulating data demonstrate that obesity and insulin resistance are associated with a more severe and faster progression of the fibrogenic process indifferent chronic liver diseases, and attention has focused on possible links between the adipose tissue and liver repair.ADIPOCYTOKINEs are cytokines secreted primarily by adipose tissue, they are relevant for adipose tissue physiology and metabolism.Alterations in the adipocytokine pattern are involved in different obesity-related diseases, such as hypertension, atherosclerosis and type II diabetes mellitus (T2DM).Numerous recent studies have analyzed the role played by adipocytokines in the process of hepatic 'wound healing' and fibrogenesis. In particular, data have accumulated on the role of adiponectin and leptin. This review summarizes the more significant and recent findings concerning the role played by different adipocytokines in hepatic fibrogenesis, discussing the actions of adipocytokines on the biology of liver cells, and their effects in different animal models. The variations in the circulating levels and intrahepatic expression of different adipocytokines in patients with fibrogenic liver diseases are also discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20370673     DOI: 10.2174/138161210791208857

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  16 in total

Review 1.  What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 2.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

3.  Topological analysis of protein co-abundance networks identifies novel host targets important for HCV infection and pathogenesis.

Authors:  Jason E McDermott; Deborah L Diamond; Courtney Corley; Angela L Rasmussen; Michael G Katze; Katrina M Waters
Journal:  BMC Syst Biol       Date:  2012-04-30

Review 4.  Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver.

Authors:  Jinyao Liu
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 5.  Genetic variants in candidate genes influencing NAFLD progression.

Authors:  Michelino Di Rosa; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2011-09-06       Impact factor: 4.599

Review 6.  A review of the role of ethanol-induced adipose tissue dysfunction in alcohol-associated liver disease.

Authors:  Thiyagarajan Gopal; Weilun Ai; Carol A Casey; Terrence M Donohue; Viswanathan Saraswathi
Journal:  Alcohol Clin Exp Res       Date:  2021-09-23       Impact factor: 3.928

7.  The β-catenin pathway contributes to the effects of leptin on SREBP-1c expression in rat hepatic stellate cells and liver fibrosis.

Authors:  Xuguang Zhai; Kunfeng Yan; Jiye Fan; Minghui Niu; Qian Zhou; Yan Zhou; Hongshan Chen; Yajun Zhou
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  Pathophysiology of NASH: perspectives for a targeted treatment.

Authors:  Fabio Marra; Sophie Lotersztajn
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 9.  Adipocytokines and hepatic fibrosis.

Authors:  Neeraj K Saxena; Frank A Anania
Journal:  Trends Endocrinol Metab       Date:  2015-02-02       Impact factor: 12.015

10.  Managing the combination of nonalcoholic Fatty liver disease and metabolic syndrome with chinese herbal extracts in high-fat-diet fed rats.

Authors:  Yi Tan; Weiguo Lao; Linda Xiao; Zhenzhong Wang; Wei Xiao; Mohamed A Kamal; J Paul Seale; Xianqin Qu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-18       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.